saveferris2009
New member
Thanks to all who participated in Phase II studies of PTC 124 (ataluren), the drug is now moving to Phase III.
With so many drugs in the pipeline, this just further emphasizes the need for <b> <u>EVERYONE </u> to participate in CF clinical trials. </b> The more people participate, the faster these drugs can come to the market (all other things equal).
If you want to see which trials are in your area, go to the CFF website: <a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/Find/
">http://www.cff.org/research/ClinicalResearch/Find/
</a>
From the CFF:
"Our biotech collaborator PTC Pharmaceuticals just announced their potential CF drug ataluren, which has shown promising results in earlier clinical trials, has moved into Phase 3 testing.
"CF patients who took ataluren (formerly PTC 124) in Phase 2 clinical trials showed improved lung function and decreased cough. The results suggest the drug improves the function of the faulty CFTR protein in people with CF - the underlying cause of the disease. Phase 3 trials will further evaluate the effectiveness and long-term safety of this potential therapy."
With so many drugs in the pipeline, this just further emphasizes the need for <b> <u>EVERYONE </u> to participate in CF clinical trials. </b> The more people participate, the faster these drugs can come to the market (all other things equal).
If you want to see which trials are in your area, go to the CFF website: <a target=_blank class=ftalternatingbarlinklarge href="http://www.cff.org/research/ClinicalResearch/Find/
">http://www.cff.org/research/ClinicalResearch/Find/
</a>
From the CFF:
"Our biotech collaborator PTC Pharmaceuticals just announced their potential CF drug ataluren, which has shown promising results in earlier clinical trials, has moved into Phase 3 testing.
"CF patients who took ataluren (formerly PTC 124) in Phase 2 clinical trials showed improved lung function and decreased cough. The results suggest the drug improves the function of the faulty CFTR protein in people with CF - the underlying cause of the disease. Phase 3 trials will further evaluate the effectiveness and long-term safety of this potential therapy."